New AccuDetect software reduces false-positive rates during mammography screening

NewsGuard 100/100 Score

Parascript, LLC, the image analysis and pattern recognition technology provider, today announced the release of AccuDetect 4.0, the next generation of its computer-aided detection (CAD) software with significant performance improvements and a greater potential for lowering false-positive rates when detecting suspicious lesions on mammograms, compared to the previous version of the product. Parascript AccuDetect 4.0 is unique in that it achieves high sensitivity and low false positive rates through the integration of several complimentary algorithms and a sophisticated voting scheme within a single CAD system.

Available for OEM customers interested in reducing false-positive rates of existing CAD systems, AccuDetect is intended to assist radiologists in the early detection of breast cancer during mammography screening exams.

AccuDetect is tuned to work with the leading full field digital and computed radiography vendors. The software recently received CE Mark approval and is deployed in the European Union.

"At Parascript, we are continually working towards improving the performance levels of our computer-aided detection algorithms to reach results comparable to the trained radiologist's eye," said Yuri Prizemin, director of product marketing for Parascript. "We are very excited to have made such significant strides as we have this year with AccuDetect."

CAD systems are typically relied upon to identify and highlight hard-to-find features and anomalies on medical images that may be indicative of cancer and bring them to the attention of radiologists. AccuDetect automatically identifies and clearly marks suspicious areas without obscuring the region of interest, enabling a more accurate interpretation of mammograms and increased detection of calcifications and masses.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Empowering Change: How Hologic is Shaping the Future of Women's Healthcare